AGÕæÈ˹ٷ½

Worthington Steel, Inc. (WS) has filed a Form 4 indicating that Executive Chairman and Director John B. Blystone received 17,065 restricted common shares on 06/27/2025 pursuant to the company’s 2023 Long-Term Incentive Plan. The transaction is coded “A,â€� signifying an equity award granted at $0 rather than an open-market purchase. After the grant, Blystone’s direct beneficial ownership rises to 236,314 shares. The award will vest on 06/27/2026, strengthening the executive’s equity stake and aligning leadership incentives with shareholders. No sales, option exercises, or derivative transactions were reported in this filing.

Worthington Steel, Inc. (WS) has filed a Form 4 indicating that Executive Chairman and Director John B. Blystone received 17,065 restricted common shares on 06/27/2025 pursuant to the company’s 2023 Long-Term Incentive Plan. The transaction is coded “A,â€� signifying an equity award granted at $0 rather than an open-market purchase. After the grant, Blystone’s direct beneficial ownership rises to 236,314 shares. The award will vest on 06/27/2026, strengthening the executive’s equity stake and aligning leadership incentives with shareholders. No sales, option exercises, or derivative transactions were reported in this filing.

Nvidia Corp. (NVDA) has filed a Form 144 indicating that President and CEO Jen-Hsun Huang intends to sell up to 75,000 shares of common stock on 30 June 2025 through broker Charles Schwab & Co. The planned transaction is valued at approximately $11.8 million, based on the filing’s stated aggregate market value. The shares were acquired via a Performance Stock Award on 20 March 2024 and will be sold on the NASDAQ exchange. The filing lists 24.4 billion shares outstanding, making the proposed sale an immaterial 0.0003 % of total shares.

The notice also discloses that Huang has executed six sales in the previous three months—totalling 375,000 shares between 20 June 2025 and 27 June 2025—for combined gross proceeds of roughly $56.7 million. Together with the upcoming sale, insider disposals reach 450,000 shares within a short window.

Because Form 144 signals an intention rather than a completed trade, the transaction may or may not occur, and no Rule 10b5-1 plan adoption date is provided in the submitted fields. Nonetheless, the filing meets disclosure requirements under SEC Rule 144, offering investors transparency into executive trading activity.

Revolution Medicines (RVMD) filed a Form 4 for director Alexis Borisy covering transactions on 26 June 2025.

• 3,142 Restricted Stock Units (RSUs) were acquired at no cost, lifting his direct common-stock position to 2,338,884 shares.
• A new stock-option grant for 11,574 shares was issued at an exercise price of $37.48, expiring on 26 Jun 2035; the award vests in full on the earlier of the first anniversary or the next annual meeting, assuming continued service.

No shares were sold, so Mr. Borisy’s net exposure to RVMD equity increased. Although the incremental RSU amount is small relative to his existing 2.3 million-share stake, the at-the-money option grant and additional RSUs reinforce alignment between the director and shareholders by incentivizing future price appreciation.

Revolution Medicines, Inc. (RVMD) filed a Form 4 disclosing routine equity awards to director Elizabeth M. Anderson on 26 June 2025.

• Restricted Stock Units (RSUs): Anderson received 3,142 shares of common stock at no cost, raising her direct beneficial ownership to 23,215 shares (inclusive of the new RSUs).
• Stock Option Grant: She was granted an option on 11,574 shares with a $37.48 exercise price, expiring 26 June 2035. The option vests in full on the earlier of the first anniversary of the grant or immediately prior to the next annual meeting, provided she remains a service provider.
• Indirect Holdings: Anderson also reports 26,990 shares held through the David W. Anderson 1996 Irrevocable Trust.
• No Dispositions: The filing records no sales of RVMD shares.

The transactions represent standard director compensation and have an immaterial impact on the company’s overall share count or governance structure. No performance metrics, strategic developments, or other material events were disclosed in this filing.

Revolution Medicines, Inc. (RVMD) filed a Form 4 disclosing routine equity awards to director Elizabeth M. Anderson on 26 June 2025.

• Restricted Stock Units (RSUs): Anderson received 3,142 shares of common stock at no cost, raising her direct beneficial ownership to 23,215 shares (inclusive of the new RSUs).
• Stock Option Grant: She was granted an option on 11,574 shares with a $37.48 exercise price, expiring 26 June 2035. The option vests in full on the earlier of the first anniversary of the grant or immediately prior to the next annual meeting, provided she remains a service provider.
• Indirect Holdings: Anderson also reports 26,990 shares held through the David W. Anderson 1996 Irrevocable Trust.
• No Dispositions: The filing records no sales of RVMD shares.

The transactions represent standard director compensation and have an immaterial impact on the company’s overall share count or governance structure. No performance metrics, strategic developments, or other material events were disclosed in this filing.

Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering $9.193 million of Contingent Income Auto-Callable Securities linked to the common stock of Amgen Inc. (AMGN). The notes are senior, unsecured obligations that mature on 29-Dec-2028 unless redeemed earlier. Each $1,000 security pays a quarterly contingent coupon of 2.625% (10.50% p.a.) when the closing price of AMGN on the relevant valuation date is at least 70 % of the initial share price ($279.11). Missed coupons may be fully ‘caught-up� if the share price subsequently meets the threshold.

The notes may be automatically redeemed on any quarterly valuation date starting 26-Sep-2025 if AMGN closes at or above the initial share price. Holders then receive par plus the due coupon (including any unpaid coupons). If not redeemed, the principal repayment depends on AMGN’s final price:

• â‰� 70 % of initial: return of principal plus final coupon (and unpaid coupons).
• < 70 % of initial: principal is reduced 1-for-1 with the share decline, exposing investors to losses of up to 100 %.

Key economic terms include a downside threshold of $195.377, no exchange listing, CUSIP 17333LBW4, and a guaranteed but unsecured payment structure. The issue price is $1,000, while the estimated value is $971.50, reflecting structuring and distribution costs: an underwriting fee of $25, a $20 selling concession, and a $5 structuring fee to Morgan Stanley Wealth Management. Secondary market liquidity is expected to be limited and solely at Citigroup Global Markets Inc.’s discretion.

Risk highlights disclosed span full principal loss below threshold, contingent and non-cumulative coupons, early redemption limiting yield, issuer and guarantor credit risk, model-based valuation, potential conflicts in hedging, and complex U.S. tax treatment. The securities do not offer any participation in AMGN price appreciation or dividends. They are intended for sophisticated investors who can tolerate equity downside, credit exposure to Citigroup, and possible illiquidity.

Revolution Medicines has entered into significant financing agreements with Royalty Pharma, including a $250 million upfront payment for tiered revenue rights from two key products: daraxonrasib (RMC-6236) and zoldonrasib (RMC-9805).

The deal includes potential additional funding tranches totaling up to $1.1 billion:

• Tranche 2: $250M tied to positive Phase 3 PDAC trial results
• Tranche 3: Up to $250M upon FDA approval
• Tranche 4: Up to $250M upon sales milestone
• Tranche 5: Up to $350M for first-line PDAC treatment success

Additionally, the company secured a $750 million term loan facility with Royalty Pharma Development Funding, structured in three tranches of $250M each. The loan bears interest at three-month SOFR (3.50% floor) plus 5.75%. This comprehensive financing package strengthens Revolution Medicines' position in advancing its RAS inhibitor pipeline, particularly for pancreatic cancer treatment.

Revolution Medicines (RVMD) General Counsel Jeff Cislini reported a sale of 1,912 shares of common stock on June 20, 2025, at a weighted average price of $39.61 per share (range: $39.26-$40.05). The transaction was executed under a pre-established 10b5-1 trading plan adopted on March 13, 2025.

Following the transaction, Cislini retains beneficial ownership of 54,093 shares, including 49,054 restricted stock units. The sale was reported through Form 4 filed on June 28, 2025, and was executed in compliance with SEC regulations. The transaction was filed by Cislini's attorney-in-fact, Jack Anders.